Ocular to present detailed SOL-1 data at the 49th Macula Society Annual Meeting on Friday, February 27, 2026, starting at 1:00 PM PT (4:00 PM ET) Company to host an investor webcast on Monday, March 2 ...
Abstract: In the ever-evolving cyber era, cyberattack threats are increasingly diverse and elusive. Precise and complete information related to cyber attacks can be utilised to create a reliable ...
Ocular Therapeutix Inc. (NASDAQ: OCUL) shares are down during Tuesday's premarket session following a significant announcement regarding their Axpaxli treatment for wet age-related macular ...
Ocular to host webcast scheduled for Tuesday, February 17, 2026, at 8:00 AM ET Detailed SOL-1 data to be presented at the 49 th Macula Society Annual Meeting BEDFORD, Mass., Feb. 13, 2026 (GLOBE ...
Oct 10 (Reuters) - Drugmaker Bristol Myers Squibb (BMY.N), opens new tab said on Friday it will acquire privately held cell therapy developer Orbital Therapeutics for $1.5 billion in cash, aiming to ...
Bristol Myers Squibb has agreed to buy privately held biotechnology company Orbital Therapeutics for $1.5 billion in cash in a deal that bolsters the drugmaker's cell-therapy portfolio. Bristol Myers ...
Bristol Myers Squibb (NYSE:BMY) has agreed to acquire privately held biotechnology company Orbital Therapeutics for $1.5 billion in cash. Orbital Therapeutics is advancing a new generation of RNA ...
Drugmaker Bristol-Myers Squibb said on Friday it will acquire privately held cell therapy developer Orbital Therapeutics for $1.5 billion in cash, aiming to diversify from legacy products facing ...
The stars have aligned for Bristol Myers Squibb and Orbital Therapeutics. Pushing deeper into in vivo cell therapies, BMS has agreed to pay $1.5 billion to buy the biotech for a pipeline led by a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results